Navigation Links
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
Date:6/22/2009

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2010. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.3 million in exchange for committed research services through Dec. 22, 2010.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)

"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."

In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such product shall no longer be covered by a valid claim of a U.S. or foreign patent or application and, generally, 10 years after the first commercial sale of any product licensed under the agreement. Wyeth may terminate the agreement without cause at any time upon 90 days' written notice.

Trubion retains the right to develop and commercialize, on its own or with others, product candidates directed to all targets not included within the agreement, including CD37.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1 / 2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the Company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the Company's future clinical development programs and the timing thereof, the Company's future regulatory filings and the timing and outcome thereof. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the Company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the Company's quarterly report on Form 10-Q for the period ended March 31, 2009, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

TRBN-G

    Contact:
    Jim DeNike
    Senior Director, Corporate Communications
    Trubion Pharmaceuticals, Inc.
    (206) 838-0500
    jdenike@trubion.com
   http://www.trubion.com


    Waggener Edstrom Worldwide Healthcare
    Amy Petty
    Senior Account Executive
    (617) 576-5788
    amyp@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
2. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
3. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
5. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
6. Trubion Announces Presentations at Upcoming Investor Conferences
7. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
8. Trubion Announces Presentations at Upcoming Investor Conferences
9. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... (mCRC) generally produce small, heterogeneous samples with limited tumor content in a large ... to be resolved, such as the need for reliable detection of low abundance ...
(Date:3/27/2017)... ... ... PMG Research is pleased to announce its participation in the 2nd ... Boston on April 3-4, 2017. The CTC conference focuses on how the industry is ... closer to the patient. Clinical Trial Collaborations also will present an inaugural conference on ...
(Date:3/24/2017)... MiMedx Group, Inc. (NASDAQ: MDXG), the leading ... allografts and patent-protected processes to develop and market advanced ... today  that it will present at the Needham Healthcare ... Parker H. "Pete" Petit, Chairman and CEO, Michael ... Cashman , EVP and Chief Commercialization Officer, and ...
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
Breaking Biology Technology:
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/13/2017)... -- Future of security: Biometric Face Matching software  ... ... Face Matching enables to match face pictures against each other or against large ... Identification Systems) ... is the fastest software for biometric Face Matching on the market. The speed ...
Breaking Biology News(10 mins):